APP
SPRY icon

Avantax Planning Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Avantax Planning Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,174
Closed -$274K – 483
2024
Q2 		$274K Hold
32,174
– – 0.01% 374
2024
Q1 		$329K Hold
32,174
– – 0.01% 349
2023
Q4 		$176K Hold
32,174
– – 0.01% 365
2023
Q3 		$122K Hold
32,174
– – 0.01% 351
2023
Q2 		$216K Hold
32,174
– – 0.01% 347
2023
Q1 		$209K Hold
32,174
– – 0.01% 351
2022
Q4 		$274K Hold
32,174
– – 0.01% 309
2022
Q3 		$170K Hold
32,174
– – 0.01% 330
2022
Q2 		$136K Hold
32,174
– – 0.01% 328
2022
Q1 		$113K Buy
+32,174
New +$140K ﹤0.01% 347

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Avantax Planning Partners's SPRY Position: Q3 2024 in Review

Avantax Planning Partners sold out of ARS Pharmaceuticals (SPRY) in Q3 2024, closing a stake of 32,174 shares — an estimated $274K sold.

Avantax Planning Partners first reported a position in SPRY in Q1 2022 and held it in 10 quarters. The position peaked at $329K in Q1 2024. 150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Avantax Planning Partners reported no remaining ARS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Avantax Planning Partners sold 32,174 ARS Pharmaceuticals shares in Q3 2024, an estimated $274K.
  • Avantax Planning Partners first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Avantax Planning Partners's ARS Pharmaceuticals position peaked at $329K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Avantax Planning Partners's 13F filing for Q3 2024, filed 14 Nov 2024.